Spotlight on the development of proprietary devices like the SG Alina pen injector platform
Piombino Dese (PD), Italy, November 4, 2021 – Stevanato Group, a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, will showcase the benefits of its integrated solutions approach at CPhI Worldwide, November 9-11, 2021. The company will be exhibiting at Fiera Milano in Milan – in the InnoPack zone in Hall 6, Booth #G20.
SG Alina is a user-friendly, disposable, variable-dose pen injector platform compatible with established therapeutic regimens as well as innovator drug therapies related to diabetes care. It features an attractive and functional design, including an easy-to-dial mechanism, optimized injection force for patient comfort, and a readable display. The pen injector platform will provide a range of customization, from dosing and color selection to a more customized industrial design based on the needs of the pharmaceutical client.
This device is just one example of Stevanato Group's efforts to be a full solution provider. Visitors to CPhI Worldwide will also have the chance to see how the organization's integrated approach supports pharma companies at every stage of the drug development process – from analytical services and drug containment solutions to automation and assembly equipment and contract manufacturing.
"The growing demand for customized products, produced faster and more cost effectively than ever before, means pharma companies are increasingly outsourcing activities to contract organizations," said Andrea Zambon, Corporate Business Development Director at Stevanato Group. "Our team is looking forward to highlighting the benefits of our full-service, integrated, flexible and modular approach for pharma companies large and small worldwide."
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. For more information, please visit www.stevanatogroup.com.
